Adverse events that occurred during the study regardless of attribution mainly included pruritus, fatigue, abdominal pain, anemia, and thrombocytopenia.958 Additionally, other potential applications of neutralizing TGF-β antibodies suggested by pre-clinical studies include wound healing,334,959,960 prostatic hyperplasia,961 pulmonary diseases,962,963 cardiovascular diseases,564,964 musculoskeletal diseases,965–968 inflammatory diseases,969,970 and Chagas disease (Trypanosoma cruzi infection).971. The gene discussed is TGFB1; the disease is Chagas disease.